Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass.
Actinium
Lutetium
PSMA
Radionuclide therapy
Tubarial salivary glands
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
26 Jul 2024
26 Jul 2024
Historique:
received:
11
06
2024
accepted:
22
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
In 2021, the tubarial salivary glands (TSGs) were newly identified on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) as macroscopic glands in the nasopharyngeal wall. However, the relative contribution of the TSGs to the total salivary gland function, and consequently on the development of xerostomia after external beam radiotherapy (EBRT) or PSMA-targeted radionuclide therapy (RNT) is not known. Therefore, we aimed to determine the presence of the TSGs and to quantify uptake in the TSGs on PSMA PET. Qualitative and quantitative analyses were performed on The TSGs were visible on 95% of the The SUVmean, SUVmax and TO-PSMA of the TSGs were most comparable to the SLSGs. However, the measured PSMA uptake may be disproportional towards the saliva production. Therefore, future studies should focus on the relation between PSMA uptake and salivary function before and after PSMA therapy.
Sections du résumé
BACKGROUND
BACKGROUND
In 2021, the tubarial salivary glands (TSGs) were newly identified on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) as macroscopic glands in the nasopharyngeal wall. However, the relative contribution of the TSGs to the total salivary gland function, and consequently on the development of xerostomia after external beam radiotherapy (EBRT) or PSMA-targeted radionuclide therapy (RNT) is not known. Therefore, we aimed to determine the presence of the TSGs and to quantify uptake in the TSGs on PSMA PET.
METHODS
METHODS
Qualitative and quantitative analyses were performed on
RESULTS
RESULTS
The TSGs were visible on 95% of the
CONCLUSIONS
CONCLUSIONS
The SUVmean, SUVmax and TO-PSMA of the TSGs were most comparable to the SLSGs. However, the measured PSMA uptake may be disproportional towards the saliva production. Therefore, future studies should focus on the relation between PSMA uptake and salivary function before and after PSMA therapy.
Identifiants
pubmed: 39060832
doi: 10.1007/s12149-024-01965-x
pii: 10.1007/s12149-024-01965-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Ling SW, de Blois E, Hooijman E, van der Veldt A, Brabander T. Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer. Pharmaceutics. 2022;14(10):2166.
doi: 10.3390/pharmaceutics14102166
pubmed: 36297601
pmcid: 9607057
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.
pubmed: 9815541
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.
doi: 10.1016/S0090-4295(98)00278-7
pubmed: 9763084
Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020;12(6):1367.
doi: 10.3390/cancers12061367
pubmed: 32466595
Yao V, Berkman CE, Choi JK, O’Keefe DS, Bacich DJ. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2010;70(3):305–16.
doi: 10.1002/pros.21065
pubmed: 19830782
Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472–83.
doi: 10.1111/j.1365-2559.2007.02635.x
pubmed: 17448023
Nishida H, Kondo Y, Kusaba T, Kadowaki H, Daa T. Immunohistochemical reactivity of prostate-specific membrane antigen in salivary gland tumors. Head Neck Pathol. 2022;16(2):427–33.
doi: 10.1007/s12105-021-01376-8
pubmed: 34420181
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256–61.
doi: 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
pubmed: 9610707
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18–28.
doi: 10.1016/1078-1439(95)00002-Y
pubmed: 21224086
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23.
doi: 10.2967/jnumed.118.219352
pubmed: 30291192
Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi KA. Radiation dosimetry in (177)Lu-PSMA-617 therapy. Semin Nucl Med. 2022;52(2):243–54.
doi: 10.1053/j.semnuclmed.2021.11.003
pubmed: 34893320
Fendler WP, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–90.
doi: 10.18632/oncotarget.12240
pubmed: 27683041
Valstar MH, de Bakker BS, Steenbakkers R, de Jong KH, Smit LA, Klein Nulent TJW, et al. The tubarial salivary glands: a potential new organ at risk for radiotherapy. Radiother Oncol. 2021;154:292–8.
doi: 10.1016/j.radonc.2020.09.034
pubmed: 32976871
Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med Biol. 2021;98–99:30–9.
doi: 10.1016/j.nucmedbio.2021.04.003
pubmed: 34020337
Sakthivel P, Thakar A, Arunraj ST, Prashanth A, Kumar R, Sharma SC, Kumar R. Physiological PSMA uptake in the tubarial salivary glands and its implications in the PARIS protocol-a first study of its kind! Clin Nucl Med. 2021;46(8):e398–405.
doi: 10.1097/RLU.0000000000003583
pubmed: 33782285
Luiting HB, van Leeuwen PJ, Remmers S, Donswijk M, Busstra MB, Bakker IL, et al. Optimal timing of prostate specific membrane antigen positron emission tomography/computerized tomography for biochemical recurrence after radical prostatectomy. J Urol. 2020;204(3):503–10.
doi: 10.1097/JU.0000000000001012
pubmed: 32149575
EANM. EARL PET/CT Accreditation User Manual Version 4.2 (May2023) ©EARL 2023. Available from: https://earl.eanm.org/wp-content/uploads/2023/05/EARL_Manual_4.2.pdf .
Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric (68)Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962–8.
doi: 10.2967/jnumed.117.193581
pubmed: 28522740
Pedersen AML, Sorensen CE, Proctor GB, Carpenter GH, Ekstrom J. Salivary secretion in health and disease. J Oral Rehabil. 2018;45(9):730–46.
doi: 10.1111/joor.12664
pubmed: 29878444
Ruigrok EAM, van Weerden WM, Nonnekens J, de Jong M. The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research. Pharmaceutics. 2019;11(11):560.
doi: 10.3390/pharmaceutics11110560
pubmed: 31671763
pmcid: 6921028
Wang F, Li Z, Feng X, Yang D, Lin M. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(1):11–26.
doi: 10.1038/s41391-021-00394-5
pubmed: 34050265
Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing (225) Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019;46(1):139–47.
doi: 10.1007/s00259-018-4135-8
pubmed: 30151743
Belli ML, Sarnelli A, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, et al. Targeted alpha therapy in mCRPC (metastatic castration-resistant prostate cancer) patients: predictive dosimetry and toxicity modeling of (225) Ac-PSMA (prostate-specific membrane antigen). Front Oncol. 2020;10:531660.
doi: 10.3389/fonc.2020.531660
pubmed: 33251129
pmcid: 7674768
Kalidindi TM, Lee SG, Jou K, Chakraborty G, Skafida M, Tagawa ST, et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2021;48(8):2642–51.
doi: 10.1007/s00259-020-05150-w
pubmed: 33495926
pmcid: 10134681
Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, et al. Preclinical evaluation of (203/212)Pb-Labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61(1):80–8.
doi: 10.2967/jnumed.119.229393
pubmed: 31253744
pmcid: 6954458
Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland OS, Juzeniene A. Evaluation of the PSMA-binding ligand (212)Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int J Mol Sci. 2021;22(9):4815.
doi: 10.3390/ijms22094815
pubmed: 34062920
pmcid: 8124365
Huang SS, DiFilippo FP, Lindner DJ, Heston WD. A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [(68)Ga]Ga-PSMA-11. EJNMMI Radiopharm Chem. 2024;9(1):7.
doi: 10.1186/s41181-024-00237-3
pubmed: 38289450
pmcid: 10828251
Agarwal K, Kumar PSN, Kumar P, Garg A, Nigam J, Silambarasan NS. Feasibility of achieving dose constraints for dysphagia aspiration-related structures and its clinical significance in intensity-modulated radiotherapy planning of head and neck cancer. Cureus. 2024;16(2):e53769.
pubmed: 38465172
pmcid: 10922219
Castelli J, Thariat J, Benezery K, Hasbini A, Gery B, Berger A, et al. Weekly adaptive radiotherapy vs standard intensity-modulated radiotherapy for improving salivary function in patients with head and neck cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(8):1056–64.
doi: 10.1001/jamaoncol.2023.1352
pubmed: 37261806
pmcid: 10236337
Weissmann T, Speer S, Putz F, Lettmaier S, Schubert P, Shariff M, et al. Reduction of elective radiotherapy treatment volume in definitive treatment of locally advanced head and neck cancer-comparison of a prospective trial with a revised simulated contouring approach. J Clin Med. 2021;10(20):4653.
doi: 10.3390/jcm10204653
pubmed: 34682782
pmcid: 8537676